Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Kurma chameleon

    How French VC Kurma is bringing industry into tech transfer before creating newcos

    Kurma Partners is using a new model for company creation to pursue disruptive discoveries from academia, with lower risk.

    Published on 1/19/2017
  • Table: BioCentury Product Profile

    Gut control Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Akkermansia muciniphila or its protein Amuc_1100 Concept Pasteurization-stabilized form of a …

    Published on 1/12/2017
  • Table: Tapping the microbiome for metabolic disease

    Gut control Targets & Mechanisms Tapping the microbiome for metabolic disease Select companies and collaborations targeting the intestinal microbiome to treat obesity and other metabolic conditions. Source: BCIQ: …

    Published on 1/12/2017
  • Gut control

    Three new avenues for using the microbiome to treat obesity

    Separate studies highlight three connections between the microbiome and obesity - a protein, a bacterial species and a gut signature - with therapeutic and prognostic utility.

    Published on 1/12/2017
  • NCATS - five, alive and kicking

    Chris Austin on NCATS' plans for the next five years

    As NCATS celebrates its fifth birthday, director Chris Austin discusses the institute's role in the translational ecosystem and its plans for the future.

    Published on 1/5/2017
  • Box: Shocking Zika

    Fever pace for Zika Product R&D Shocking Zika While other groups are focusing on standard virus-based vaccine platforms and nucleic acid modalities, Heat Biologics Inc. and the University of Miami are going down a …

    Published on 12/22/2016
  • Figure: Choose your weapon

    Fever pace for Zika Product R&D Choose your weapon In response to the Zika virus epidemic, companies are developing at least eight different modalities of antiviral vaccines and therapeutics, each with distinct …

    Published on 12/22/2016
  • Figure: Race against time

    Fever pace for Zika Product R&D Race against time A timeline of select news events, funding announcements and scientific developments in the recent Zika epidemic. In October 2013, an outbreak of Zika virus in …

    Published on 12/22/2016
  • Figure: Zika's exponential moment

    Fever pace for Zika Product R&D Zika's exponential moment First discovered in 1947, Zika virus has only been considered an acute threat to worldwide public health in the last two years. The number of Zika-related …

    Published on 12/22/2016
  • Table: Zika vaccines and therapeutics

    Fever pace for Zika Product R&D Zika vaccines and therapeutics Since the beginning of 2016, at least 18 companies and institutions have announced plans to develop vaccines or therapeutics against Zika infection. As…

    Published on 12/22/2016
  • Fever pace for Zika

    Zika's momentum could push nucleic acid vaccines over the finish line

    Zika has prompted aggressive development of a slew of new antiviral platforms that could stock the war chest for the world's next epidemic.

    Published on 12/22/2016
  • Table: Ras and p53 technologies

    p53 and Ras: Back from the dead Product R&D Ras and p53 technologies Select technologies being employed to develop drugs against the challenging targets Ras and p53. At least seven companies are developing …

    Published on 12/15/2016
  • p53 and Ras - Back from the dead

    Why drug developers haven't given up on p53 and Ras

    New therapeutic modalities and mutation-specific approaches to drug development may finally make the previously intractable targets p53 and Ras druggable.

    Published on 12/15/2016
  • The Sharing Economy

    Pharma is opening up its libraries to draw in external partners

    In the latest iteration of open innovation, pharmas are starting to lower their guard and embark on large-scale compound-sharing programs with other companies and academics.

    Published on 12/8/2016
  • Table: Pharma compound-sharing deals

    The Sharing Economy Strategy Pharma compound-sharing deals Select pharma compound-sharing partnerships. Each partnership involves sharing, swapping or screening compounds from at least one pharma company's library.…

    Published on 12/8/2016
  • Not a peripheral story

    Beyond peripheral autoimmunity in Type I diabetes

    By looking in pancreatic islets rather than blood, a UMass team has uncovered a trove of new antigens that drive Type I diabetes.

    Published on 12/1/2016
  • Figure: A lethal halo

    Not a peripheral story Targets & Mechanisms A lethal halo In a Nature Medicine study published in October, researchers from the University of Massachusetts Medical School profiled islet-infiltrating T cells from …

    Published on 12/1/2016
  • Figure: Commercialization gap

    China's dysfunctional patent flood Strategy Commercialization gap Although Chinese universities file many more patents each year than academic institutes in the U.S. and Europe, they lag behind when it comes to …

    Published on 11/17/2016
  • Figure: No contest

    China's dysfunctional patent flood Strategy No contest Chinese universities beat U.S. and U.K. universities by an order of magnitude when it comes to patenting their technologies. The chart shows the numbers of …

    Published on 11/17/2016
  • China's dysfunctional patent flood

    How poor patents hinder tech transfer in China

    A mountain of poor quality patents is hampering commercialization of Chinese science. The question is whether government reforms will change the landscape.

    Published on 11/17/2016
  • Chemistry beyond candidates

    AZN chemists tackle common problems in compound innovation

    AstraZeneca is broadcasting its stepped-up chemistry focus with a tetrad of publications on innovative molecule design.

    Published on 11/10/2016
  • Figure: Chemistry quartet

    Chemistry beyond candidates Tools & Techniques Chemistry quartet AstraZeneca plc (LSE:AZN; NYSE:AZN) published a series of four studies addressing key stumbling blocks in medicinal chemistry that the company …

    Published on 11/10/2016
  • Box: Going, going, gone

    The next (re)generation Strategy Going, going, gone The failure of first-wave regenerative medicine companies still looms large for industry and investors. Three high-profile busts in the last three years could be …

    Published on 11/3/2016
  • Figure: Regenerative Venture

    The next (re)generation Strategy Regenerative Venture In the last decade, VC investment in regenerative medicine companies has been highly variable, but the last three years have seen a big uptick in private …

    Published on 11/3/2016
  • The next (re)generation

    Why investors both want and worry about regenerative medicine

    Despite scientific progress in regenerative medicine, stakeholders fear technical challenges and company missteps could turn off both investors and regulators.

    Published on 11/3/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993